VOYXACT (sibeprenlimab-szsi)
IMMUNOSUPPRESSANTS - APRIL INHIBITORS · IMMUNOGLOBULIN A NEPHROPATHY
Otsuka Pharmaceutical Co., Ltd.
Drug class
Immunosuppressants - APRIL Inhibitors
Immunosuppressants in the APRIL inhibitor class are targeted biologic therapies designed to disrupt signaling mediated by a proliferation-inducing ligand (TNFSF13). Read more about Immunosuppressants - APRIL Inhibitors
2 drugs in this class 2 manufacturers
Drugs in Immunosuppressants - APRIL Inhibitors
TRUTAKNA (atacicept-vymj)
IMMUNOMODULATOR, B-LYMPHOCYTE STIMULATOR (BLYS)-SPEC INHIB · IMMUNOGLOBULIN A NEPHROPATHY
VERA THERAPEUTI
Filter & compare in the drug finder →
Opens the drug finder with Immunosuppressants - APRIL Inhibitors preselected. Add indication or manufacturer filters there.
Immunosuppressants in the APRIL inhibitor class are targeted biologic therapies designed to disrupt signaling mediated by a proliferation-inducing ligand (TNFSF13).
By neutralizing APRIL alone or in combination with B-cell activating factor, these agents inhibit downstream binding to key receptors—such as BCMA and TACI—thereby reducing the survival of antibody-producing plasma cells and suppressing pathogenic immunoglobulin synthesis.
Their primary therapeutic role is in autoimmune disorders driven by aberrant B-cell and plasma-cell activity, most notably immunoglobulin A nephropathy to reduce pathogenic galactose-deficient IgA1 and proteinuria, as well as systemic lupus erythematosus.
-
patsnap.com
Immunosuppressants in the APRIL inhibitor class are targeted biologic therapies designed to disrupt signaling mediated by a proliferation-inducing ligand (TNFSF13) By neutralizing APRIL alone or in combination with B-cell activating factor, these agents inhibit downstream binding to key receptors—such as BCMA and TACI—thereby reducing the survival of antibody-producing plasma cells and suppressing pathogenic immunoglobulin synthesis
-
kactusbio.com
Immunosuppressants in the APRIL inhibitor class are targeted biologic therapies designed to disrupt signaling mediated by a proliferation-inducing ligand (TNFSF13) By neutralizing APRIL alone or in combination with B-cell activating factor, these agents inhibit downstream binding to key receptors—such as BCMA and TACI—thereby reducing the survival of antibody-producing plasma cells and suppressing pathogenic immunoglobulin synthesis
-
frontiersin.org
By neutralizing APRIL alone or in combination with B-cell activating factor, these agents inhibit downstream binding to key receptors—such as BCMA and TACI—thereby reducing the survival of antibody-producing plasma cells and suppressing pathogenic immunoglobulin synthesis Their primary therapeutic role is in autoimmune disorders driven by aberrant B-cell and plasma-cell activity, most notably immunoglobulin A nephropathy to reduce pathogenic galactose-deficient IgA1 and proteinuria, as well as s...
-
nih.gov
Their primary therapeutic role is in autoimmune disorders driven by aberrant B-cell and plasma-cell activity, most notably immunoglobulin A nephropathy to reduce pathogenic galactose-deficient IgA1 and proteinuria, as well as systemic lupus erythematosus
-
biopharminternational.com
Their primary therapeutic role is in autoimmune disorders driven by aberrant B-cell and plasma-cell activity, most notably immunoglobulin A nephropathy to reduce pathogenic galactose-deficient IgA1 and proteinuria, as well as systemic lupus erythematosus
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.